BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37714925)

  • 21. NUP98-fusion transcripts characterize different biological entities within acute myeloid leukemia: a report from the AIEOP-AML group.
    Bisio V; Zampini M; Tregnago C; Manara E; Salsi V; Di Meglio A; Masetti R; Togni M; Di Giacomo D; Minuzzo S; Leszl A; Zappavigna V; Rondelli R; Mecucci C; Pession A; Locatelli F; Basso G; Pigazzi M
    Leukemia; 2017 Apr; 31(4):974-977. PubMed ID: 27890935
    [No Abstract]   [Full Text] [Related]  

  • 22. A minicircuitry of microRNA-9-1 and RUNX1-RUNX1T1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia.
    Fu L; Shi J; Liu A; Zhou L; Jiang M; Fu H; Xu K; Li D; Deng A; Zhang Q; Pang Y; Guo Y; Hu K; Zhou J; Wang Y; Huang W; Jing Y; Dou L; Wang L; Xu K; Ke X; Nervi C; Li Y; Yu L
    Int J Cancer; 2017 Feb; 140(3):653-661. PubMed ID: 27770540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The chromosome translocation t(7;11)(p15;p15) in acute myeloid leukemia results in fusion of the NUP98 gene with a HOXA cluster gene, HOXA13, but not HOXA9.
    Taketani T; Taki T; Ono R; Kobayashi Y; Ida K; Hayashi Y
    Genes Chromosomes Cancer; 2002 Aug; 34(4):437-43. PubMed ID: 12112533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RUNX1-ETO Depletion in t(8;21) AML Leads to C/EBPα- and AP-1-Mediated Alterations in Enhancer-Promoter Interaction.
    Ptasinska A; Pickin A; Assi SA; Chin PS; Ames L; Avellino R; Gröschel S; Delwel R; Cockerill PN; Osborne CS; Bonifer C
    Cell Rep; 2019 Sep; 28(12):3022-3031.e7. PubMed ID: 31533028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Secreted-frizzled related protein 1 is a transcriptional repression target of the t(8;21) fusion protein in acute myeloid leukemia.
    Cheng CK; Li L; Cheng SH; Ng K; Chan NP; Ip RK; Wong RS; Shing MM; Li CK; Ng MH
    Blood; 2011 Dec; 118(25):6638-48. PubMed ID: 22031861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of c-KIT mutations on expression of the RUNX1/RUNX1T1 fusion transcript in t(8;21)-positive acute myeloid leukemia patients.
    Park SH; Chi HS; Cho YU; Jang S; Park CJ
    Leuk Res; 2013 Jul; 37(7):784-9. PubMed ID: 23528260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NUP98 is fused to PMX1 homeobox gene in human acute myelogenous leukemia with chromosome translocation t(1;11)(q23;p15).
    Nakamura T; Yamazaki Y; Hatano Y; Miura I
    Blood; 1999 Jul; 94(2):741-7. PubMed ID: 10397741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The t(8;21) fusion protein RUNX1-ETO downregulates PKM2 in acute myeloid leukemia cells.
    Yan JS; Li YD; Liu SH; Yin QQ; Liu XY; Xia L; Lu Y
    Leuk Lymphoma; 2017 Aug; 58(8):1985-1988. PubMed ID: 28092997
    [No Abstract]   [Full Text] [Related]  

  • 29. A novel NUP98/RARG gene fusion in acute myeloid leukemia resembling acute promyelocytic leukemia.
    Such E; Cervera J; Valencia A; Barragán E; Ibañez M; Luna I; Fuster O; Perez-Sirvent ML; Senent L; Sempere A; Martinez J; Martín-Aragonés G; Sanz MA
    Blood; 2011 Jan; 117(1):242-5. PubMed ID: 20935257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Faggot cells in acute myeloid leukemia with t(7;11)(p15;p15) and NUP98-HOXA9 fusion.
    Yanagisawa H; Mizuta S; Kawabata H; Fujimoto S; Sakai T; Iwao-Kawanami H; Kawanami T; Yamada K; Fukushima T; Kyoda K; Masaki Y
    Ann Hematol; 2021 Aug; 100(8):2121-2123. PubMed ID: 32514625
    [No Abstract]   [Full Text] [Related]  

  • 31. Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA.
    Duployez N; Nibourel O; Marceau-Renaut A; Willekens C; Helevaut N; Caillault A; Villenet C; Celli-Lebras K; Boissel N; Jourdan E; Dombret H; Figeac M; Preudhomme C; Renneville A
    Am J Hematol; 2014 Jun; 89(6):610-5. PubMed ID: 24616160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decoding of exon splicing patterns in the human RUNX1-RUNX1T1 fusion gene.
    Grinev VV; Migas AA; Kirsanava AD; Mishkova OA; Siomava N; Ramanouskaya TV; Vaitsiankova AV; Ilyushonak IM; Nazarov PV; Vallar L; Aleinikova OV
    Int J Biochem Cell Biol; 2015 Nov; 68():48-58. PubMed ID: 26320575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transcription of the AML1/ETO chimera is guided by the P2 promoter of the AML1 gene in the Kasumi-1 cell line.
    Markova EN; Kantidze OL; Razin SV
    Gene; 2012 Dec; 510(2):142-6. PubMed ID: 22995345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and laboratory studies of 17 patients with acute myeloid leukemia harboring t(7;11)(p15;p15) translocation.
    Wei S; Wang S; Qiu S; Qi J; Mi Y; Lin D; Zhou C; Liu B; Li W; Wang Y; Wang M; Wang J
    Leuk Res; 2013 Sep; 37(9):1010-5. PubMed ID: 23800796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proleukemic RUNX1 and CBFbeta mutations in the pathogenesis of acute leukemia.
    Engel ME; Hiebert SW
    Cancer Treat Res; 2010; 145():127-47. PubMed ID: 20306249
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel RUNX1-C11orf41 fusion gene in a case of acute myeloid leukemia with a t(11;21)(p14;q22).
    Abe A; Katsumi A; Kobayashi M; Okamoto A; Tokuda M; Kanie T; Yamamoto Y; Naoe T; Emi N
    Cancer Genet; 2012 Nov; 205(11):608-11. PubMed ID: 23102734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.
    Yin JA; O'Brien MA; Hills RK; Daly SB; Wheatley K; Burnett AK
    Blood; 2012 Oct; 120(14):2826-35. PubMed ID: 22875911
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Core-binding factor leukemia hijacks the T-cell-prone PU.1 antisense promoter.
    van der Kouwe E; Heller G; Czibere A; Pulikkan JA; Agreiter C; Castilla LH; Delwel R; Di Ruscio A; Ebralidze AK; Forte M; Grebien F; Heyes E; Kazianka L; Klinger J; Kornauth C; Le T; Lind K; Barbosa IAM; Pemovska T; Pichler A; Schmolke AS; Schweicker CM; Sill H; Sperr WR; Spittler A; Surapally S; Trinh BQ; Valent P; Vanura K; Welner RS; Zuber J; Tenen DG; Staber PB
    Blood; 2021 Oct; 138(15):1345-1358. PubMed ID: 34010414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia.
    Kim T; Moon JH; Ahn JS; Ahn SY; Jung SH; Yang DH; Lee JJ; Shin MG; Choi SH; Lee JY; Tyndel MS; Lee HY; Kim KH; Cai Y; Lee YJ; Sohn SK; Min YH; Cheong JW; Kim HJ; Zhang Z; Kim DDH
    Sci Rep; 2020 Nov; 10(1):20119. PubMed ID: 33208771
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches.
    Hatlen MA; Wang L; Nimer SD
    Front Med; 2012 Sep; 6(3):248-62. PubMed ID: 22875638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.